Dongwoo Chae, M.D., Ph.D., Director of Clinical Strategy, is a graduate of Yonsei University’s College of Medicine where he earned is MD in 2006 and his PhD in 2017. He has been actively engaged in industry collaborations that enhance our understanding of PK/PD and optimal dosing regimens for both established and novel investigational therapeutic compounds. Of particular interest has been the clinical implementation of phage therapy due to their unique PK/PD characteristics. In 2011 Dr. Chae began his residency at Yonsei University’s Health System in Neurology and later in clinical pharmacology. In 2019 he started a career as an assistant professor and has since been working as an associate professor from 2025 within the Department of Pharmacology at Yonsei University’s College of Medicine. As of 2025, he holds the position of president of PAGK (Population Approach Group Korea), a research society founded to advance the study of pharmacometrics. Dr. Chae’s recent contributions to the pharmacology and bacteriophage field include the authored articles “Bridging in vitro and in vivo insights: A PKPD model for effective phage therapy against multidrug-resistant Pseudomonas aeruginosa”, “Phage-host-immune system dynamics in bacteriophage therapy: basic principles and mathematical models”, and “Model-informed precision dosing in vancomycin treatment”.